Publication | Closed Access
Efficacy and safety of sofosbuvir/velpatasvir in a real‐world chronic hepatitis C genotype 3 cohort
32
Citations
18
References
2020
Year
The SOF/VEL ± RBV is a safe and efficacious treatment option for GT3 HCV patients in a real-world setting. SOF/VEL with RBV may be considered for decompensated GT3 HCV patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1